Page last updated: 2024-10-31

metyrapone and Adenocystic Carcinoma

metyrapone has been researched along with Adenocystic Carcinoma in 2 studies

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sugawara, M1
Hagen, GA1
Vingerhoeds, AC1
Thijssen, JH1
Schwarz, F1

Other Studies

2 other studies available for metyrapone and Adenocystic Carcinoma

ArticleYear
Ectopic ACTH syndrome due to salivary gland adenoid cystic carcinoma.
    Archives of internal medicine, 1977, Volume: 137, Issue:1

    Topics: Adrenocorticotropic Hormone; Aged; Autopsy; Carcinoma, Adenoid Cystic; Cushing Syndrome; Female; Hor

1977
Detection of an ACTH-secreting bronchial carcinoid tumour eighteen months after adrenalectomy for Cushing's syndrome.
    Acta endocrinologica, 1971, Volume: 67, Issue:4

    Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Bronc

1971